NCT02953782

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

Conditions

• Solid Tumor
• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Magrolimab	Administered intravenously
DRUG	Cetuximab	Administered intravenously

Timeline

• Start date: 2016-11-02
• Primary completion: 2020-02-10
• Completion: 2020-02-10
• First posted: 2016-11-03
• Last updated: 2021-03-01
• Results posted: 2021-03-01

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study